Alnylam infectious, endocrine/metabolic, cancer news
Alnylam provided a pipeline update and said it expects to have six to seven programs in clinical development by YE15, exceeding the goals set in the company's original "Alnylam 5x15" plan. The company said it expects at least two programs in Phase III testing and five to six with human proof-of-concept (POC) data by that time. Alnylam's ALN-TTR02 is in the Phase III APOLLO trial to treat familial amyloidosis polyneuropathy (FAP), a predominant clinical manifestation of transthyretin (TTR)-mediated amyloidosis. Its ALN-TTRsc is in Phase II testing for TTR-mediated amyloidosis, with Phase III testing slated to start by year end. Early this year, the company will begin Phase I testing of ALN-AT3 to treat hemophilia and rare bleeding disorders, with initial data slated for late 2014.
The company said it expects to submit INDs late this year or early next year for ALN-CC5 for complement-mediated diseases, ALN-AS1 for hepatic prophyrias and ALN-PCSsc for hypercholesterolemia. In January 2011, Alnylam first announced its 5x15 plan to have five short interfering RNA (siRNA) programs for Orphan and rare diseases in late-stage clinical development by 2015 (see BioCentury, Jan. 10, 2011). ...